ALK-Abelló A/S (AKABY) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Horsholm, Denmark. The current CEO is Carsten Hellmann.
AKABY has IPO date of 2013-09-05, 2,566 full-time employees, listed on the Other OTC.
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
